curacle co.,ltd. (KOSDAQ: A365270)
Health Care · Biotechnology · KR
₩9,770.00
-4.22% today · +33.5% 1Y
curacle co.,ltd. (KOSDAQ: A365270) operates in the Biotechnology industry within the Health Care sector. The company is valued at $161.02M.
Over the last twelve months the share price has gained 33.5%, trading between 4.40K and 20.75K.
Tweenvest scores curacle co.,ltd. across four factors: quality 50/100, value 83/100. Its strongest factor is value.
A365270 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $161.02M
- Revenue (TTM)
- $5.32M
- P/E
- —
- EPS
- -377.58
- Dividend yield
- —
- Beta (5Y)
- 2.10
- 52-week high
- ₩20,750.00
- 52-week low
- ₩4,400.00
- Avg volume (3M)
- —
- Shares outstanding
- 22.16M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GC Cell CorporationKOSDAQ: A144510 | $163.20M | ₩14,600.00 | +0.14% |
| Protara Therapeutics, Inc.NasdaqGM: TARA | $162.81M | $2.77 | +0.54% |
| Bioneer CorporationKOSDAQ: A064550 | $162.42M | ₩8,460.00 | -1.28% |
| Nkarta, Inc.NasdaqGS: NKTX | $161.16M | $2.17 | -3.56% |
| Pacific Edge LimitedNZSE: PEB | $160.23M | NZ$0.23 | -8.00% |
| Satellos Bioscience Inc.TSX: MSCL | $159.25M | CA$10.71 | -10.82% |
| Coherus Oncology, Inc.NasdaqGM: CHRS | $159.14M | $1.03 | -3.74% |
| Organogenesis Holdings Inc.NasdaqCM: ORGO | $158.27M | $1.23 | -4.65% |
Figures last refreshed Oct 11, 2026.